Morphic to Participate in Jefferies Global Healthcare Conference
31 mai 2024 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells
21 mai 2024 08h00 HE
|
Morphic Therapeutic
in vivo video presented at DDW 2024 show small molecule α4β7 inhibition rapidly increases rolling velocity & flux of B cells similar to antibodies
Morphic to Participate in RBC Capital Markets Global Healthcare Conference
09 mai 2024 16h05 HE
|
Morphic Therapeutic
Morphic COO, Dr. Marc Schegerin to take part in fireside chat at RBC Healthcare conference on 5/15
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
25 avr. 2024 07h00 HE
|
Morphic Therapeutic
MORF ends 1Q24 with $659 million, cash into 2H27; phase 2b study of MORF-057 in UC continues on target; anticipate GARNET phase 2 in Crohn's to begin 2Q
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
19 mars 2024 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic to Participate in March Investor Conferences
05 mars 2024 16h05 HE
|
Morphic Therapeutic
WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023
22 févr. 2024 07h00 HE
|
Morphic Therapeutic
MORF ends '23 with $700 million, cash into 2H27; MORF-057 EMERALD-2 UC trial enrolling on target; to begin Ph 2 GARNET trial of 057 in Crohn's disease 1H24
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 16h05 HE
|
Morphic Therapeutic
Morphic CEO. Praveen Tipirneni, MD, to present at JP Morgan Healthcare Conference January 10, 2024
Morphic to Present at November Investor Conferences
10 nov. 2023 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
03 nov. 2023 07h00 HE
|
Morphic Therapeutic
-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of...